H-HOPE Intervention for Premature Infants
Trial Summary
The trial protocol does not specify whether participants need to stop taking their current medications. However, since the trial focuses on behavioral interventions for infants and their parents, it is unlikely that stopping medications is required. Please consult with the trial coordinators for more specific guidance.
The available research shows that the H-HOPE Intervention is effective because it is a standardized program that includes both infant-directed and parent-directed components. It has been documented to help with feeding, growth, and development in premature infants. The study aims to make H-HOPE the standard care in multiple neonatal intensive care units, indicating its recognized benefits. Compared to other treatments, H-HOPE focuses on both the infant's needs and parental involvement, which is not commonly provided as routine care in many hospitals.
12345The provided research does not directly address safety data for the H-HOPE Intervention. However, it mentions that H-HOPE is a standardized behavioral intervention with documented efficacy, suggesting it has been studied for effectiveness. The research also highlights the need for safety monitoring in NICUs, but specific safety data for H-HOPE is not detailed in the abstracts.
16789Yes, the H-HOPE Intervention is promising for premature infants. It helps improve feeding, growth, and development, and enhances mother-infant interactions. It also increases the frequency of behaviors that prepare infants for feeding and keeps them more alert, which is important for their development.
12101112Eligibility Criteria
This trial is for preterm infants born between 23-35 weeks gestational age, now at 31-32 weeks post menstrual age, and their parents. Infants may be on oxygen or IV therapy and previously intubated but must be ready for social interaction. Parents of any background can join; only one infant per multiple births will be analyzed.Inclusion Criteria
Participant Groups
H-HOPE Intervention is already approved in United States for the following indications:
- Supporting early brain maturation, health, and development in preterm infants